JOURNAL OF CARDIOVASCULAR PHARMACOLOGY AND THERAPEUTICS

Scope & Guideline

Exploring the intersection of cardiology and pharmacology.

Introduction

Delve into the academic richness of JOURNAL OF CARDIOVASCULAR PHARMACOLOGY AND THERAPEUTICS with our guidelines, detailing its aims and scope. Our resource identifies emerging and trending topics paving the way for new academic progress. We also provide insights into declining or waning topics, helping you stay informed about changing research landscapes. Evaluate highly cited topics and recent publications within these guidelines to align your work with influential scholarly trends.
LanguageEnglish
ISSN1074-2484
PublisherSAGE PUBLICATIONS INC
Support Open AccessYes
CountryUnited Kingdom
TypeJournal
Convergefrom 1996 to 2024
AbbreviationJ CARDIOVASC PHARM T / J. Cardiovasc. Pharmacol. Ther.
Frequency6 issues/year
Time To First Decision-
Time To Acceptance-
Acceptance Rate-
Home Page-
Address2455 TELLER RD, THOUSAND OAKS, CA 91320

Aims and Scopes

The Journal of Cardiovascular Pharmacology and Therapeutics aims to advance knowledge in the field of cardiovascular pharmacotherapy. It publishes research focusing on the development, efficacy, and safety of pharmacological treatments for cardiovascular conditions, as well as innovative therapeutic approaches and their clinical implications.
  1. Pharmacological Interventions for Cardiovascular Diseases:
    The journal emphasizes studies on various pharmacological agents used to treat cardiovascular diseases, including novel therapies and existing medications, assessing their safety and efficacy.
  2. Clinical Outcomes and Real-World Evidence:
    Research that evaluates the outcomes of cardiovascular treatments in clinical practice, including observational studies and real-world data analyses, is a core focus.
  3. Mechanistic Studies in Cardiovascular Pharmacology:
    Investigations into the underlying mechanisms of action of cardiovascular drugs, including molecular and cellular pathways, are regularly featured.
  4. Therapeutic Innovations and Trials:
    The journal places a strong emphasis on clinical trials and innovative therapeutic approaches, including combination therapies and new drug formulations.
  5. Impact of Comorbidities on Cardiovascular Treatment:
    Research examining how comorbid conditions (e.g., diabetes, chronic kidney disease) affect cardiovascular treatment outcomes is a prominent theme.
The Journal of Cardiovascular Pharmacology and Therapeutics has increasingly embraced new and emerging themes in cardiovascular research. Recent publications indicate a shift towards exploring innovative therapies and addressing contemporary challenges in cardiovascular care.
  1. SGLT2 Inhibitors and Heart Failure:
    There is a growing focus on the role of SGLT2 inhibitors in treating heart failure, especially in patients with diabetes, highlighting their multifaceted benefits.
  2. Personalized Medicine and Genotyping:
    Emerging studies emphasize the importance of personalized medicine approaches, including genotyping for anticoagulant therapy, reflecting a trend towards individualized treatment strategies.
  3. Impact of Lifestyle Factors on Cardiovascular Health:
    Research exploring the effects of lifestyle factors—such as diet, physical activity, and smoking—on cardiovascular health and treatment outcomes is gaining traction.
  4. Cardiovascular Effects of Novel Therapies:
    An increased interest in the cardiovascular implications of non-cardiovascular drugs and therapies, including those used in cancer treatment, is evident in recent publications.
  5. Integrative Approaches to Cardiovascular Care:
    There is a notable trend towards integrative strategies combining pharmacological and non-pharmacological interventions, emphasizing holistic patient management.

Declining or Waning

While the journal has consistently focused on cardiovascular pharmacotherapy, certain themes have seen a decline in publication frequency or relevance. These waning scopes may reflect shifting research priorities or advancements in treatment paradigms.
  1. Traditional Antihypertensive Agents:
    Research focusing solely on traditional antihypertensive medications has decreased, as newer agents and combination therapies are gaining prominence.
  2. Static Observational Studies:
    The prevalence of static observational studies without innovative designs or significant clinical implications appears to be declining, as the journal increasingly favors studies with robust methodologies and real-world applications.
  3. Basic Science without Clinical Relevance:
    Papers focusing solely on basic science aspects of cardiovascular pharmacology, lacking direct clinical relevance or application, have been published less frequently.

Similar Journals

American Journal of Preventive Cardiology

Elevating Knowledge in Cardiovascular Prevention.
Publisher: ELSEVIERISSN: 2666-6677Frequency: 4 issues/year

American Journal of Preventive Cardiology, published by ELSEVIER, is a premier Open Access journal that has been making significant strides in the field of cardiology since its inception in 2020. With an impressive impact factor and recognized as a Q1 journal in the Cardiology and Cardiovascular Medicine category as of 2023, it ranks 77th out of 387 in the Scopus database, placing it in the 80th percentile of its field. The journal aims to promote the latest research and practices in preventive cardiology, addressing the global burden of cardiovascular diseases through a combination of innovative findings and practical applications. With the advantage of Open Access, all published articles are readily available to researchers, professionals, and students worldwide, fostering a broad dissemination of knowledge and encouraging collaboration across disciplines. Based in Amsterdam, Netherlands, the journal is committed to advancing the science and prevention of heart disease, making it an essential resource for those dedicated to improving cardiovascular health.

Cardiovascular Diagnosis and Therapy

Transforming Cardiovascular Health with Cutting-Edge Discoveries
Publisher: AME PUBLISHING COMPANYISSN: 2223-3652Frequency: 6 issues/year

Cardiovascular Diagnosis and Therapy, an esteemed journal in the field of Cardiology and Cardiovascular Medicine, is published by AME PUBLISHING COMPANY, based in Hong Kong, China. With an ISSN of 2223-3652 and an E-ISSN of 2223-3660, this open-access journal aims to present cutting-edge research that significantly advances diagnostic and therapeutic practices in cardiovascular health. Recognized for its impact, it holds a 2023 category quartile ranking of Q2 and is positioned at rank #124 out of 387 in Scopus, reflecting its noteworthy contribution to medical literature with a percentile of 68th. The journal welcomes contributions that span various aspects of cardiovascular research, including clinical trials, epidemiological studies, and innovative therapeutic approaches, making it a vital resource for researchers, practitioners, and students alike, committed to improving cardiovascular care.

CIRCULATION

Elevating Cardiology: Where Innovation Meets Excellence.
Publisher: LIPPINCOTT WILLIAMS & WILKINSISSN: 0009-7322Frequency: 50 issues/year

CIRCULATION is a premier journal in the field of cardiology and cardiovascular medicine, published by Lippincott Williams & Wilkins. With a distinguished history dating back to 1950, the journal has consistently been at the forefront of critical research, showcasing significant advancements and discoveries in cardiovascular health. It holds a remarkable Q1 ranking in both the fields of Cardiology and Physiology (medical) according to the 2023 category quartiles, demonstrating its influential role among the top publications in these disciplines. With an impressive Scopus ranking, placed 3rd out of 387 in Cardiology and 2nd out of 113 in Physiology, CIRCULATION is essential reading for researchers, practitioners, and students passionate about advancing their understanding of heart health and related medical sciences. Although the journal is not open access, it continues to foster scholarly exchange and innovation in cardiovascular research, making it an indispensable resource for quality insights and groundbreaking studies.

Archives of Cardiovascular Diseases

Pioneering research and collaboration in cardiology.
Publisher: ELSEVIER MASSON, CORP OFFISSN: 1875-2136Frequency: 12 issues/year

The Archives of Cardiovascular Diseases, published by Elsevier Masson, stands as a leading journal in the field of cardiology and cardiovascular medicine, with an impressive impact factor that underscores its relevance and influence. This esteemed journal, recognized in the Q2 category for both cardiology and miscellaneous medicine, aims to disseminate groundbreaking research, innovative methodologies, and clinical advancements that can shape the future of cardiovascular health. With its diverse array of open access options, researchers and students alike have the ability to engage with high-quality content, ensuring that cutting-edge findings are accessible globally. Since its inception in 2008, the journal has actively contributed to the advancement of knowledge in cardiovascular diseases, fostering collaboration among clinicians, researchers, and educators. Headquartered in Paris, France, Archives of Cardiovascular Diseases remains committed to enhancing our understanding of cardiovascular health and improving patient outcomes worldwide.

Expert Review of Clinical Pharmacology

Elevating the standards of clinical pharmacology for better health.
Publisher: TAYLOR & FRANCIS LTDISSN: 1751-2433Frequency: 12 issues/year

Expert Review of Clinical Pharmacology, published by TAYLOR & FRANCIS LTD, is a leading peer-reviewed journal dedicated to the field of clinical pharmacology, with a strong focus on the development and application of pharmacological therapies in patient care. Boasting an impressive impact, the journal ranks in the first quartile across multiple categories including Medicine (miscellaneous), Pharmacology (medical), and Pharmacology, Toxicology and Pharmaceutics (miscellaneous), reflecting its influential position within the scientific community. With a Scopus ranking of #6 in General Pharmacology, Toxicology and Pharmaceutics, the journal also achieves a commendable 93rd percentile, further emphasizing its importance as a resource for researchers and clinicians alike. As it continues to publish innovative reviews and research articles from 2008 until 2024, the Expert Review of Clinical Pharmacology plays an essential role in advancing knowledge, improving clinical practice, and fostering collaboration among experts in pharmacology, thereby driving forward the field's evolution towards better patient outcomes.

Cardiovascular Journal of Africa

Connecting Africa's cardiovascular community and expertise.
Publisher: CLINICS CARDIVE PUBL PTY LTDISSN: 1995-1892Frequency: 6 issues/year

Welcome to the Cardiovascular Journal of Africa, an esteemed publication dedicated to advancing the fields of Cardiology and Cardiovascular Medicine. Established in 1994 and published by CLINICS CARDIVE PUBL PTY LTD, this journal serves as a vital platform for researchers, practitioners, and students interested in innovative cardiovascular research and clinical practice within the African context and beyond. With a Q3 ranking in both relevant categories as of 2023, this journal contributes significantly to the growing corpus of medical literature. Although access is non-open, the journal features a diverse array of peer-reviewed articles that explore groundbreaking findings and practical applications in cardiovascular health, fostering knowledge exchange among professionals. Situated in South Africa, the Cardiovascular Journal of Africa is not just a repository of academic research; it is a cornerstone in the fight against cardiovascular diseases, addressing the unique challenges faced by populations across the continent.

PROGRESS IN CARDIOVASCULAR DISEASES

Driving Progress in Cardiovascular Science
Publisher: W B SAUNDERS CO-ELSEVIER INCISSN: 0033-0620Frequency: 6 issues/year

PROGRESS IN CARDIOVASCULAR DISEASES is a leading journal in the field of cardiology and cardiovascular medicine, published by W B SAUNDERS CO-ELSEVIER INC. With an impressive impact factor that places it in the esteemed Q1 quartile of its category, this journal ranks among the top 32 out of 387 journals in its field, positioning itself in the 91st percentile. Since its inception in 1958 and continuing until 2024, it has been a prolific source of cutting-edge research, reviews, and clinical insights that contribute significantly to the understanding and treatment of cardiovascular diseases. Although it does not currently offer open access options, the journal's rigorous peer-review process ensures that all published content meets the highest standards of scientific excellence. As a key resource for researchers, practitioners, and students alike, PROGRESS IN CARDIOVASCULAR DISEASES serves as an indispensable tool for advancing knowledge and practice in cardiovascular health.

VASCULAR PHARMACOLOGY

Connecting research and practice in vascular medicine.
Publisher: ELSEVIER SCIENCE INCISSN: 1537-1891Frequency: 12 issues/year

Vascular Pharmacology, published by Elsevier Science Inc, is a leading journal in the fields of pharmacology and molecular medicine, dedicated to advancing our understanding of vascular biology and therapeutic interventions. With an impressive impact factor reflecting its significant contribution to the scientific community, this journal seeks to publish ground-breaking research that elucidates the molecular mechanisms underlying vascular function and disease, as well as the pharmacological impact of new therapeutic agents. The journal operates under a dual access model, allowing for both subscription and open access options, ensuring that vital research is accessible to a wide audience. As of 2023, it holds a prestigious position in the Q1 category for pharmacology and ranks well in molecular medicine and physiology, reflecting its high quality and relevance. Whether you are a researcher, clinician, or student, Vascular Pharmacology serves as an essential resource to stay at the forefront of cardiovascular pharmacotherapy and vascular biology.

Minerva Cardiology and Angiology

Innovating heart health through groundbreaking research.
Publisher: EDIZIONI MINERVA MEDICAISSN: 2724-5683Frequency: 6 issues/year

Minerva Cardiology and Angiology, published by EDIZIONI MINERVA MEDICA, is a prominent journal in the field of cardiology and cardiovascular medicine, with an ISSN of 2724-5683 and E-ISSN of 2724-5772. Established in 2021, this journal aims to foster the dissemination of cutting-edge research, clinical practice guidelines, and innovative methodologies relevant to cardiovascular health. As of 2023, it holds a commendable Q3 quartile rank in its category, reflecting its growing influence within the scientific community. The journal is indexed in Scopus, where it ranks #221 out of 387 in its field, placing it in the 43rd percentile overall. Although it currently does not offer Open Access options, articles published in Minerva Cardiology and Angiology contribute significantly to ongoing discussions and advancements in heart and vascular health. The journal serves as an invaluable resource for researchers, healthcare professionals, and students seeking to stay informed on the latest developments in cardiology.

Anatolian Journal of Cardiology

Connecting Global Hearts with Cutting-edge Cardiovascular Knowledge.
Publisher: KARE PUBLISSN: 2149-2263Frequency: 12 issues/year

The Anatolian Journal of Cardiology, published by KARE PUBL, stands as a vital resource in the field of Cardiology and Cardiovascular Medicine. With an ISSN of 2149-2263 and E-ISSN 2149-2271, this Open Access journal has been fostering the dissemination of critical research since 2001, ensuring that high-quality content is freely available to a global audience. Based in Turkey, the journal aims to bridge gaps in cardiological knowledge through rigorous peer-reviewed articles that span a wide range of topics, from innovative clinical practices to groundbreaking research findings. While its current ranking places it in the Q3 category of cardiology journals, the Anatolian Journal of Cardiology continues to strive towards enhancing its impact, currently holding a Scopus rank of 236 out of 387. Researchers, practitioners, and students alike will find this journal an essential platform for keeping abreast of the latest developments in cardiovascular health.